You are here: Industry Insights > Calquence

News List

SMC backs five new medicines for NHS use pharmatimes
June 09, 2021
The Scottish Medicines Consortium (SMC) has accepted five new medicines for use by NHS Scotland in its June 2021 decisions.
Calquence Demonstrates Fewer Incidences of Atrial Fibrillation vs Ibrutinib in Patients with Leukaemia americanpharmaceuticalreview
June 09, 2021
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in ...
New oral chronic lymphocytic leukaemia treatment made available on NHS europeanpharmaceuticalreview
March 22, 2021
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
NICE backs AstraZeneca’s Calquence for CLL pharmatimes
March 18, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Calquence for use on the NHS to treat a common form of leukaemia.
Calquence tops Imbruvica in chronic lymphocytic leukaemia study pharmatimes
January 26, 2021
AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) hit the primary endpoint in a Phase III study in chronic lymphocytic leukaemia (CLL).
NICE backs AZ' Calquence for chronic lymphocytic leukaemia pharmatimes
December 09, 2020
The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).
Calquence shows long-term efficacy and tolerability in MCL pharmatimes
December 08, 2020
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca's Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up ...
Calquence Approved in EU for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
November 18, 2020
AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in ..
Calquence fails to prevent respiratory failure in COVID-19 patients europeanpharmaceuticalreview
November 16, 2020
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
EU OK for AZ’s Calquence in CLL pharmatimes
November 11, 2020
The European Commission has approved AstraZeneca’s Calquence (acalabrutinib)for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).

Previous page 1 2 Next page